ClinicalTrials.gg
CompletedNCT05910164PELGRAZUpdated Dec 19, 2024

Patient Preference Between a Prefilled Syringe or a Prefilled Pen Device for Administration of Pegfilgrastim

An observational study in Patient Preference, Febrile Neutropenia, Drug-Induced and Patient Satisfaction, sponsored by Institut Rafael. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-19.

Sponsored by Institut Rafael · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-crossover
Time perspective
Prospective
Enrollment
150
Ages
18 Years and older
Sex
All
01

Study summary

Febrile neutropenia (NF) is a common serious complication of cancer chemotherapy. Outpatient management of chemotherapy treatments is made essential by the volume of patients treated, respect for their quality of life and the lack of hospitalization resources.

The prevention of NF is well documented and its success depends on the risks of developing NF related to the type of chemotherapy protocol used and the profile of the patient and his disease.

Pegfilgrastim (G-CSF, biosimilar medicine) injection has been shown to prevent (febrile) neutropenia. It is routinely prescribed on an outpatient basis for patients treated with chemotherapy (CT), several thousand times a year in our geographical area.

In order to take into account patient preferences and help clinical decision-making, this study will be conducted on the basis of self-administered questionnaires. The aim of the research is to assess patient preference for receiving administration of PELGRAZ (Accord Healthcare) using a prefilled syringe or a prefilled pen device. In a second step, this study will evaluate the learning of the patient and his autonomy during a pen self-injection guided by a nurse.

Read the detailed description

Febrile neutropenia (NF) is a common serious complication of cancer chemotherapy. Outpatient management of chemotherapy treatments is made essential by the volume of patients treated, respect for their quality of life and the lack of hospitalization resources.

The prevention of NF is well documented and its success depends on the risks of developing NF related to the type of chemotherapy protocol used and the profile of the patient and his disease.

Pegfilgrastim (G-CSF, biosimilar medicine) injection has been shown to prevent (febrile) neutropenia. It is routinely prescribed on an outpatient basis for patients treated with chemotherapy (CT), several thousand times a year in our geographical area.

In order to take into account patient preferences and help clinical decision-making, this study will be conducted on the basis of self-administered questionnaires.

This research involves the administration/use of a product (PELGRAZ, Accord Healthcare) within its intended purpose. PELGRAZ prefilled syringe or prefilled pen are available on the European Union market.

The study will be carried out using a crossover design. Two modes of administration (syringe and pen) will be compared. Each subject will receive either the sequence syringe then pen, or pen then syringe.

The trial will be conducted among 150 cancer patients for whom a chemotherapy followed by the administration of pegfilgrastim is indicated.

The primary endpoint is a composite endpoint consisting of several parameters related to patient preference.

02

Conditions studied

  • Patient Preference
  • Febrile Neutropenia, Drug-Induced
  • Patient Satisfaction

Keywords

  • patient preference
  • pegfilgrastim
  • chemotherapy prophylaxis
  • febrile neutropenia
  • survey
  • questionnaires
03

In context

Patient Preference

114 studies on the registry are indexed under Patient Preference; 28 are open to participants now.

This study's enrollment of 150 is below the median of 200 across 56 observational studies indexed under Patient Preference.

Browse Patient Preference studies →

Lead sponsor

Institut Rafael is the lead sponsor of 6 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

150 patients for whom a chemotherapy treatment followed by PELGRAZ administration is indicated

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years old and older
  • Patients with solid tumors, Hodgkin's lymphoma, non-Hodgkin's lymphoma and receiving myelosuppressive chemotherapy with a risk of NF of 10-20% (individual risk factors), or ≥ 20% (primary prevention of neutropenia) and receiving PELGRAZ ® in accordance with CPR
  • Prediction of the risk of NF without filgrastim or pegfilgrastim determined according to the recommendations of the EORTC
  • ≤ 2
  • Free and obtained
  • Patient affiliated to a social security system or beneficiary of such a scheme

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • Breastfeeding
  • Patients receiving concurrent radiotherapy
  • Second cancer treated with chemotherapy
  • Participation in any other clinical trial within 30 days prior to recruitment
  • Concomitant myelosuppressive therapy, e.g. ex. therapy
  • History of severe reaction to drugs intended for use and/or drugs derived from E. coli
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Observational model
Case-crossover
Time perspective
Prospective
Enrollment
150 participants (actual)
Patient registry
No

Groups and cohorts

  • A) administration starting with prefilled syringe

    - Group A = Phase 1 then phases 2, 3, 4 The study protocol consists of 4 different stages * Phase 1: injection by pre-filled syringe by a state-certified nurse (IDE) * Phase 2: pen injection guided (thanks to the detailed information) by the IDE * Phase 3: injection by pen in autonomy supervised by the IDE (can only interfere in case of non-compliance with the injection protocol) = Learning phase * Phase 4: injection by pen in complete autonomy, patient alone

    Device: PELGRAZ prefilled syringe or PELGRAZ prefilled pen

  • B) administration starting with prefilled pen

    - Group B = Phase 2, 3, 4 then phase 1 The study protocol consists of 4 different stages * Phase 1: injection by pre-filled syringe by a state-certified nurse (IDE) * Phase 2: pen injection guided (thanks to the detailed information) by the IDE * Phase 3: injection by pen in autonomy supervised by the IDE (can only interfere in case of non-compliance with the injection protocol) = Learning phase * Phase 4: injection by pen in complete autonomy, patient alone

    Device: PELGRAZ prefilled syringe or PELGRAZ prefilled pen

Interventions

  • DevicePELGRAZ prefilled syringe or PELGRAZ prefilled pen

    PELGRAZ prefilled syringe or PELGRAZ prefilled pen https://www.ema.europa.eu/en/medicines/human/EPAR/pelgraz

06

What researchers measure

Primary outcomes

  1. questionnaire

    The primary endpoint is a composite endpoint consisting of several parameters related to patient preference

    Time frame: 120 days

Secondary outcomes

  1. questionnaire, specific questions

    1. patient learning and empowerment during self-injection 2. pain evaluation 3. duration of treatment; 4. patient satisfaction; 5. overview of the health, physical and psychological conditions of the patient according to his own perception;

    Time frame: 120 days

07

Study locations

1 site
  • Institut Rafael
    Levallois-Perret, Ile-de-France 92300, France
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in Sep 2023, 3 months.

Of 30 observational studies under Patient Preference, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 57. This study's 3 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2023
First posted
Jun 18, 2023
StartActual
Jun 9, 2023
Primary completionActual
Sep 9, 2023
CompletionActual
Oct 9, 2024
Last update
Dec 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05910164
Lead sponsor
Institut Rafael
Responsible party
Sponsor
First posted
Jun 18, 2023
Start date
Jun 9, 2023
Primary completion
Sep 9, 2023
Completion
Oct 9, 2024
Last update
Dec 19, 2024

Study contacts

Alain TOLEDANO, MD
principal investigator · Institut Rafael

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion